quantisnow
FeedTopReportsPricing
⌘K
Live feed
12:36:00·26d
PRRelease
Nektar Therapeutics logo

Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting

NKTR· Nektar Therapeutics
Health Care
Original source

Companies

  • NKTR
    Nektar Therapeutics
    Health Care

Recent analyst ratings

  • Mar 24UpdateWedbush$70.00
  • Mar 17UpdateTD Cowen-
  • Feb 10UpdateWilliam Blair-
  • Nov 26UpdateCitigroup$102.00
  • Jun 24UpdateBTIG Research$100.00
  • Jun 24UpdateH.C. Wainwright$120.00

Related

  • PR12h
    Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
  • SEC23h
    SEC Form 8-K filed by Nektar Therapeutics
  • SEC23h
    SEC Form 424B5 filed by Nektar Therapeutics
  • PR2d
    Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
  • SEC3d
    SEC Form 424B5 filed by Nektar Therapeutics
  • SEC3d
    Nektar Therapeutics filed SEC Form 8-K: Regulation FD Disclosure
  • PR3d
    Nektar Therapeutics Announces Proposed Public Offering
  • SEC3d
    Nektar Therapeutics filed SEC Form 8-K: Regulation FD Disclosure
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022